In Q1 2015, the Pelion Healthcare Group's revenue was up 11.5%, its gross margin grew by 20.4%, while its net profit reached PLN 13.9m.
The highest growth rate was reported by the retail segment (up 25%), with the growth driven primarily by the acquisition of the Natura beauty store chain in Q4 2014, which contributed PLN 94.8m to the Group's revenue in Q1 2015.Factoring out the effect of the acquisition, the retail segment expanded by 5.9%, chiefly on the back of higher sales by the Dbam o Zdrowie pharmacies. This means that the measures undertaken in the retail segment in Poland in the previous periods and continued in Q1 2015 started to produce the expected effects, reversing the negative trends seen in 2014.
The Group's market position was strengthened as a result, as the growth of the retail market in Poland was offset by a higher number of pharmacies, driving down the number of transactions per an average statistical pharmacy, with sales of an average pharmacy growing much slower than the market.
The Pelion Healthcare Group's revenue improvement was also supported by a very strong growth of the Polish pharmaceutical market. Wholesale distribution to pharmacies was up 11.9%, the retail market expanded by 8.5%, and sales to hospitals grew by 5.4%. In the period under review, the Lithuanian market shrank by 0.8%, which may have been related to customers shifting some of their purchases to the last months of 2014 in anticipation of Lithuania's entry into the eurozone, and should be viewed as a short-term trend.
In Q1 2015, Pelion companies worked to meet the needs of pharmacies and patients by providing modern services of the highest quality. PGF implemented tools for independent pharmacies, enhancing their operating efficiency. Work continued on the development of Doz direct, an innovative platform providing a closed, tightly controlled and fully secure system for distribution of drugs from the manufacturer to the patient.
The acquisition of the Natura beauty store chain in 2014 improved the Group's gross margin, but it also increased operating expenses. Consequently, the acquisition contributed negatively to the performance in Q1 2015. Unlike pharmacies, beauty stores record their weakest sales in the first quarter of the year. The higher expenses were also related to sales-support activities and the doz direct system. That innovative distribution platform, implemented since mid-2014, is yet to achieve its anticipated share in the structure of purchases. Therefore, the additional costs are not yet fully covered by the additional margin.
In each of Pelion Healthcare Group's business lines, steps are being taken to meet the 2015 objectives and ensure the Group's improved performance in a longer time horizon.
Plans for the coming months
WHOLESALE TO PHARMACIES
SALES TO HOSPITALS
SERVICES TO MANUFACTURERS
Pelion's objective remains to consolidate its position as the leader of the healthcare market and the forerunner in e-health innovation, in particular by implementing new technical solutions in the area of customer service. Pelion is building its competitive strength by offering top quality, fast and reliable services, and by meeting the needs of patients and trading partners.
The table below presents the Q1 2015 financial highlights, along with comparative year-on-year data:
Q1 2015 | Q1 2014 | Change (%)* | |
Revenue (PLNm) | 2,174 | 1,950 | 11.5% |
EBITDA (PLNm) | 44.3 | 48.0 | -7.7% |
EBITDA margin (%) | 2.0% | 2.5% | +0.5 pp |
Operating profit (PLNm) | 32.2 | 39.3 | -18.1% |
Operating margin (%) | 1.5% | 2.0% | +0.5 pp |
Net profit attributable to owners of the parent (PLNm) | 13.9 | 24.5 | -43.0% |
Net margin (%) | 0.6% | 1.3% | -0.7pp |
Earnings per share (PLN) | 1.25 | 2.18 | -42.7% |
Pelion S.A. Press Office
Phone: (+48 42) 200 75 94
Fax: (+48 42) 200 75 35
Email: biuro_prasowe@pelion.eu
distributed by |